“Iqela le-SNIPR BIOME lichulumancile ngesi siganeko sibalulekileyo, kwaye sijonge phambili ekuqaliseni ulingo lwezonyango e-US kamva kulo nyaka, sivavanya itekhnoloji yethu ekhethekileyo ye-CRISPR. I-SNIPR001 yeyona asethi yethu eqhubekileyo, kwaye sinebhongo kakhulu ngomzamo weqela osizise apha” utshilo uGqr. Christian Grøndahl, umseki kunye ne-CEO.

Ulingo lwezonyango lungavula indlela yohlobo olutsha lonyango oluchanekileyo oluza kujoliswa ngokukhethekileyo kwi-E. coli kwizigulane ezinomhlaza ezine-hematological malignancies - ezizii-cancer ezichaphazela igazi, umongo, kunye ne-lymph nodes. Ezi zigulana zisengozini yokwanda kosulelo lwegazi olusongela ubomi ngenxa yesi sifo, unyango lwechemotherapy kwaye, okubalulekileyo, ukudluliselwa kwe-pathogen ukusuka emathunjini, apho i-E. coli ingomnye wabadlali ababalulekileyo ekubangeleni usulelo.

I-SNIPR001 ijolise ekujoliseni i-E. coli ibhaktheriya emathunjini, kwaye ngaloo ndlela inqande ukuhanjiswa kwezi bhaktheriya kwigazi, ngelixa ishiya ibhaktheriya ye-commensal kwi-microbiome yesigulane ingachaphazeleki. Indlela kunye ne-SNIPR001 isebenzisa i-novel application ye-proprietary CRISPR / Cas iteknoloji yethu ekukhetheni ukuphelisa ibhaktheriya ye-E. coli emathunjini. Le ndlela ichanekileyo inokuguqula indlela usulelo lwe-E. coli oluthintelwa kwaye luphathwe ngayo, ngakumbi kwiwadi yomhlaza.

Namhlanje, akukho nyango oluvunyiweyo lwe-prophylactic therapy kwesi silungiselelo.

"Ngokusekwe kwidatha yethu yangaphambi kweklinikhi kunye ne-SNIPR001 sikholelwa ukuba itekhnoloji yethu ibambe amandla amakhulu ekuyileni amayeza asekwe kwi-CRISPR angomso ngokuchasene nosulelo olubeka ubomi emngciphekweni kunye nokulungelelanisa izifo ezinxulumene ne-microbiome" utshilo uGqr. Milan Zdravkovic, iGosa eliyiNtloko lezoNyango kunye neNtloko ye-R&D kwi-SNIPR Biome. "Ngokunyuka kwe-anti-microbial resistance kukho imfuno ephuthumayo yabaviwa beziyobisi ezinoveli ukuba baphathe iibhaktheriya ezosulelayo, ezifana ne-E. coli, kwaye siyayibulela intsebenziswano kunye nombutho ongenzi nzuzo, i-CARB-X kwi-SNIPR001".

I-SNIPR001 ngowokuqala kwabaviwa abaninzi abanonyango, njengoko kugxininiswe nguDkt Christian Grøndahl: "Sakha umbhobho oqinileyo we-CRISPR ye-asethi kwaye singaphezu komdla wethu kwizifo ezithathelwanayo, intsebenziswano kunye ne-MD Anderson Cancer Centre kwi-immuno-oncology, kunye neNovo Nordisk ekusebenziseni itekhnoloji yokuguqula imfuza kwi-microbiome. Siyavuya ukuphonononga amandla apheleleyo etekhnoloji yethu ye-CRISPR kwixesha elizayo”.

INTO ONOKUYITHATHA KWELI NQAKU:

“We are building a strong pipeline of novel CRISPR assets and have beyond our interest in infectious diseases, collaborations with the MD Anderson Cancer Center on immuno-oncology, and with Novo Nordisk on applying gene-modulation technologies on the microbiome.
coli bacteria in the gut, and thereby prevent the translocation of these bacteria to the bloodstream, while leaving the commensal bacteria in the patient’s microbiome unaffected.
These patients are at increased risk of life-threatening bloodstream infections due to the disease, to chemotherapy treatment and, importantly, to pathogen translocation from the gut, in which E.